Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025.

Truist lowered the firm’s price target on Amgen (AMGN) to $298 from $333 and keeps a Hold rating on the shares as part of a broader research ...

In the latest market close, Amgen (AMGN) reached $262.05, with a +1.34% movement compared to the previous day. This change outpaced the S&P 500's 1.11% loss on the day. Meanwhile, the Dow experienced ...

Amgen Inc. closed $84.79 short of its 52-week high ($346.85), which the company achieved on July 25th.

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

Shares of Amgen Inc. AMGN slipped 1.01% to $258.59 Monday, on what proved to be an all-around mixed trading session for the ...

Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.38 on 7th ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Amgen (AMGN – Research Report), with a ...

After opening its first facility in Ohio this year, biopharmaceutical processor Amgen has purchased an additional 22 acres ...

Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...

Here's why Amgen increased its land holdings in New Albany, even though the pharma giant has plenty of room for expansion on ...